Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.

@article{Hu2006TargetingMK,
  title={Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.},
  author={Yiguo Hu and Sarah Swerdlow and Theodore M. Duffy and Roberto Simon Weinmann and Francis Y. F. Lee and Shaoguang Li},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  year={2006},
  volume={103 45},
  pages={16870-5}
}
It is generally believed that shutting down the kinase activity of BCR-ABL by imatinib will completely inhibit its functions, leading to inactivation of its downstream signaling pathways and cure of the disease. Imatinib is highly effective at treating human Philadelphia chromosome-positive (Ph(+)) chronic myeloid leukemia (CML) in chronic phase but not Ph(+) B cell acute lymphoblastic leukemia (B-ALL) and CML blast crisis. We find that SRC kinases activated by BCR-ABL remain fully active in… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 152 extracted citations

TGF-β in Human Disease

Springer Japan • 2013
View 20 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-2 of 2 references

Cancer Cell 7:129–141

E Weisberg, PW Manley, +7 authors E Hall-Meyers
2005

M Ed Ic a L Sc Ie N Ce

Hu
PNAS November • 1987

Similar Papers

Loading similar papers…